TrialInvestigational new drugs2009

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.

R Dreicer et al.PubMed ↗Publisher ↗

No numbers read from the abstract.